As of 3:59pm ET
| -0.67 / -2.70%|
The 11 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 35.00, with a high estimate of 47.00 and a low estimate of 20.00. The median estimate represents a +44.99% increase from the last price of 24.14.
The current consensus among 13 polled investment analysts is to Buy stock in Myriad Genetics Inc. This rating has held steady since May, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.